Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tailoring anti-complement therapeutics.

C L Harris1, D A Fraser, B P Morgan

  • 1Complement Biology Group, Department of Medical Biochemistry, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, UK. harriscl@cardiff.ac.uk

Biochemical Society Transactions
|November 21, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity.

Clinical and experimental immunology·2023
Same author

The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade.

Human molecular genetics·2021
Same author

Growth, tolerance, and DHA and ARA status of healthy term infants receiving formula with two different ARA concentrations: Double-blind, randomized, controlled trial.

Prostaglandins, leukotrienes, and essential fatty acids·2019
Same author

Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex.

Thrombosis research·2016
Same author

Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse.

Clinical and experimental immunology·2015
Same journal

TDP-43 proteinopathy as a biomarker and therapeutic target in amyotrophic lateral sclerosis.

Biochemical Society transactions·2026
Same journal

Advancing the monitoring of organelle contact sites in vitro and in vivo.

Biochemical Society transactions·2026
Same journal

Mechanisms influencing transient cytoplasmic protein targeting to intracellular lipid droplets.

Biochemical Society transactions·2026
Same journal

Replication associated nuclear DNA mismatch repair across kingdoms.

Biochemical Society transactions·2026
Same journal

Phosphatases of regenerating liver downregulate PTEN to promote tumorigenesis.

Biochemical Society transactions·2026
Same journal

Implications of Rho GTPase signaling in cancer immunotherapy.

Biochemical Society transactions·2026
See all related articles

Anticomplement therapies, developed from natural regulators, now offer treatments for diseases caused by immune system overactivation. Novel strategies improve drug delivery and minimize side effects by targeting disease sites.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • The complement system is crucial for immune surveillance but can cause self-tissue damage.
  • Complement-mediated inflammation drives pathologies in diseases like rheumatoid arthritis and dementia.

Purpose of the Study:

  • To review the development of anticomplement therapeutics.
  • To discuss strategies for enhancing anticomplement drug efficacy and delivery.

Main Methods:

  • Review of first-generation anticomplement agents (unmodified natural regulators).
  • Analysis of recent strategies for drug improvement, including targeted delivery and extended half-life.
  • Exploration of prodrug approaches for site-specific activation.

Main Results:

  • Understanding natural complement control has enabled therapeutic inhibition.

Related Experiment Videos

  • Development of anticomplement agents has progressed from basic forms to advanced strategies.
  • Novel delivery methods aim to minimize systemic side effects.

    • Conclusions:

    • Anticomplement therapy is a viable treatment for diseases involving complement dysregulation.
    • Ongoing research focuses on optimizing anticomplement drugs for improved safety and efficacy.
    • Targeted delivery and prodrug strategies represent the future of anticomplement therapeutics.